arrow
K

Keunchil Park

Samsung Medical Center
H指数:113
被引数:7.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study

Amivantamab-化疗在EGFR外显子20插入的非小细胞肺癌中的应用:来自III期PAPILLON研究的治疗交叉和其他终点的影响

2025-11-030
OAAI
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

患者报告结局和症状进展时间来自PAPILLON研究:amivantamab联合化疗对比化疗作为表皮生长因子受体(EGFR)外显子20插入突变型晚期非小细胞肺癌的一线治疗

2025-10-030
PRE
Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer

颅内和系统性进展:在经铂类治疗的表皮生长因子受体外显子20插入突变型晚期非小细胞肺癌中接受阿曼曲单抗治疗

2025-05-100
PRE
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC

RELAY研究:厄洛替尼联合ramucirumab或安慰剂在未治疗、EGFR突变型转移性NSCLC中的最终总生存期

2024-11-015
PRE
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

生物标志物定向靶向治疗联合durvalumab治疗晚期非小细胞肺癌: 2期伞形试验

2024-02-1310
OAAI
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets
2024-02-014
OA
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
2023-11-3091
PRE
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC

一线Selpercatinib或化疗和Pembrolizumab治疗RET融合阳性NSCLC

2023-11-1678
OA
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
2023-09-1429
OAAI
Comprehensive molecular characterization of mitochondrial genomes in human cancers (vol 52, pg 342, 2020)

人类癌症中线粒体基因组的综合分子特征 (第52卷,342页,2020)

2023-03-210
OAAI